New painkiller may reduce opioid use after breast reduction
NCT ID NCT05891613
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tested a long-acting painkiller (liposomal bupivacaine) against a standard one (bupivacaine hydrochloride) in 32 women having breast reduction surgery. The goal was to see which provides better pain relief and reduces the need for stronger opioid painkillers in the first three days after surgery. Participants rated their pain on a 0-10 scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST REDUCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.